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Objectives
 Review pathophysiology and current therapeutic 
management of patients with Alzheimer’s disease
 Discuss new drug targets and therapies for the 
treatment of dementia in patients with Alzheimer’s 
disease
 Evaluate clinical impact of new drug therapies on 
disease progression in early/late phases of 
Alzheimer’s disease
Prevalence 
 5.7 million Americans are living with Alzheimer’s
 By 2050, this number is projected to rise nearly to nearly 
14 million
 In 2018, the cost of Alzheimer’s disease to the United 
States was $277 billion with costs expected to rise as 
high as $1.1 trillion by 2050
Alzheimer's Association Facts and Figures. 2018. 
. 
Prevalence
 Alzheimer’s disease is the 6th leading cause of death 
in the United States 
 Deaths from Alzheimer’s have increased by 123% from 
2000 to 2015 
 1 IN 3 Senior citizens die from Alzheimer’s or another 
dementia, killing more than prostrate and breast cancer 
combined
Alzheimer's Association Facts and Figures. 2018. 
. 
 Age > 65 years 
 Family History 
 Head Injury 
 Poor cardiovascular health 
 Ethnicity 
 African American and Latino 
 Genetics 
 Apolipoprotein E ε4 allele
 Presenilin 1  (PSEN-1) & Presenilin 2 (PSEN-2) 
mutation 
 Trisomy 21 (Down Syndrome) 
Risk Factors 
Alzheimer's Association. 2018. 
. 
Pathophysiology
Neurodegenerative 
Amyloid Plaques
•Altered 
APP 
Processing
•Excess 
Beta 
Amyloid 
Formation
Neurofibrillary Tangles
Hyper-
phosphorylation 
of Tau
Microtubule 
destabilization 
Scarpini E, Galimberti D, Ghezzi L. Drug Design, Development and Therapy. 2013:1471. 
. 
APP= Amyloid Precursor Protein 
 Amyloid Precursor Protein (APP) is a 
transmembrane protein expressed at high levels in 
the brain
 Primary function unknown
 Implicated in the regulation of synapse 
formation, neuronal plasticity, and iron export
 Plays a crucial role in the development of 
amyloid plaques
Pathophysiology
Scarpini E, Galimberti D, Ghezzi L. Drug Design, Development and Therapy. 2013:1471. 
. 
Pathophysiology
 APP is cleaved by either α-secretase, β-secretase, 
or γ-secretase 
 Cleavage by α-secretase and γ-secretase
soluble monomer 
 Cleavage by β-secretase and γ-secretase 
insoluble monomer  toxic oligomers  amyloid 
plaques  
Pathophysiology
Scarpini E, Galimberti D, Ghezzi L. Drug Design, Development and Therapy. 2013:1471. 
. 
Pathophysiology
 Microtubules play a crucial role in organelle/nutrient 
transport and in maintaining the architecture of the 
neuron. 
 Tau proteins help to maintain the structure of the 
microtubules
 Hyperphosphorylation of the tau protein causes de-
stabilization of microtubules 
 Overtime the tau protein develop into tangles and 
the neuron dies
Pathophysiology
Scarpini E, Galimberti D, Ghezzi L. Drug Design, Development and Therapy. 2013:1471. 
. 
Pathophysiology
Neurofibrillary tangles= 
within the neuron 
Amyloid plaques= 
outside the neuron 
Pathophysiology
Scarpini E, Galimberti D, Ghezzi L. Drug Design, Development and Therapy. 2013:1471. 
. 
 Cholinergic neurons located in the basal forebrain 
are severely lost
 Synaptic loss is the principal correlate of disease 
progression 
 Loss of Cholinergic neurons contributes to memory 
and attention deficits
Pathophysiology
Ferreira-Viera TH, et al. Alzheimers disease 2016; 14: 101-115
. 
Pathophysiology
 Excitatory glutamatergic neurotransmission via N-
methyl-d-aspartate (NMDA) receptor is critical for 
synaptic plasticity and survival of neurons
 Excessive NMDA receptor activity causes 
excitotoxicity and promotes cell death
 Potential mechanism of neurodegeneration
Pathophysiology
Wang R, et al. Journal of Alzheimers Disease. 2017;57 :1041-1048. 
. 
Pathophysiology
Pathophysiology
Current Therapeutic Management 
Donepezil 
(Aricept®)
Rivastigmine 
(Exelon®)
Galantamine 
(Razadyne®)
Birks J, Harvey R. Cochrane Database of Systematic Reviews. 2018;(6). 
Scarpini E, Galimberti D, Ghezzi L. Drug Design, Development and Therapy. 2013:1471. 
. 
Memantine 
(Namenda®)
Donepezil & 
Memantine 
(Namzaric®)
Current Therapeutic Management 
Donepezil (Aricept®)
 Indicated for treatment of mild, moderate, or severe 
dementia of Alzheimer’s disease
 Reversible Acetylcholinesterase Inhibitor
 Prevents the breakdown of acetylcholine in the synaptic 
cleft 
 Available as ODT or tablet 
Birks J, Harvey R. Cochrane Database of Systematic Reviews. 2018;(6). 
Scarpini E, Galimberti D, Ghezzi L. Drug Design, Development and Therapy. 2013:1471. 
. 
Aricept [prescribing information]. Pfizer. 2015. 
Current Therapeutic Management 
Donepezil (Aricept®)
 Adverse Reactions: 
 > 10%: Insomnia, nausea, diarrhea, infection, accidental 
injury 
 ≥ 1% to 10%: Headache, pain, abnormal dreams, 
dizziness, personality disorder, weight loss, vomiting, 
anorexia, dyspepsia, gastrointestinal hemorrhage, 
bruises 
 Monitoring parameters: mental status, weight, symptoms of 
GI intolerance, symptoms of active or occult GI bleeding 
Birks J, Harvey R. Cochrane Database of Systematic Reviews. 2018;(6). 
Scarpini E, Galimberti D, Ghezzi L. Drug Design, Development and Therapy. 2013:1471. 
. 
Aricept [prescribing information]. Pfizer. 2015. 
Current Therapeutic Management 
Rivastigmine (Exelon®)
 Indicated for treatment of mild or moderate dementia of 
Alzheimer’s disease
 Reversible Acetylcholinesterase Inhibitor
 Prevents the breakdown of acetylcholine in the synaptic 
cleft 
 Available as capsule or transdermal patch 
Birks J, Harvey R. Cochrane Database of Systematic Reviews. 2018;(6). 
Scarpini E, Galimberti D, Ghezzi L. Drug Design, Development and Therapy. 2013:1471. 
. 
Exelon [prescribing information]. Novartis 2015. 
Current Therapeutic Management 
Rivastigmine (Exelon®)
 Adverse Reactions: 
 > 10%: Dizziness, headache, agitation, falling, weight 
loss, tremor, nausea, vomiting, abdominal pain, anorexia, 
diarrhea   
 ≥ 1% to 10%: Fatigue, insomnia, confusion, depression, 
exacerbation of Parkinson disease, urinary tract infection 
 Monitoring parameters: mental status, weight, symptoms of 
GI intolerance
Birks J, Harvey R. Cochrane Database of Systematic Reviews. 2018;(6). 
Scarpini E, Galimberti D, Ghezzi L. Drug Design, Development and Therapy. 2013:1471. 
. 
Exelon [prescribing information]. Novartis 2015. 
Current Therapeutic Management 
Galantamine (Razadyne®)
 Indicated for treatment of mild to moderate dementia  of 
Alzheimer’s disease
 Reversible Acetylcholinesterase Inhibitors
 Prevents the breakdown of acetylcholine in the synaptic 
cleft 
 Modulates nicotinic acetylcholine receptors to increase 
release of acetylcholine 
 Available as extended release capsule, tablet, or solution 
Birks J, Harvey R. Cochrane Database of Systematic Reviews. 2018;(6). 
Scarpini E, Galimberti D, Ghezzi L. Drug Design, Development and Therapy. 2013:1471. 
. 
Razadyne [prescribing information]. Janssen 2016. 
Current Therapeutic Management 
Galantamine (Razadyne®)
 Adverse Reactions: 
 > 10%: Nausea, vomiting
 ≥ 1% to 10%: Dizziness, headache, depression, fatigue, 
falling, weight loss, decreased appetite, diarrhea, 
abdominal pain, tremor
 Monitoring parameters: mental status, weight
Birks J, Harvey R. Cochrane Database of Systematic Reviews. 2018;(6). 
Scarpini E, Galimberti D, Ghezzi L. Drug Design, Development and Therapy. 2013:1471. 
. 
Razadyne [prescribing information]. Janssen 2016. 
Current Therapeutic Management 
Memantine (Namenda®)
 Indicated for treatment of moderate to severe dementia of  
Alzheimer’s Disease 
 NMDA Antagonist
 Binds to the intra-pore magnesium site of the glutamate 
NMDA receptor blocking the channel under conditions of 
excessive stimulation
 Available as extended release capsule, tablet, or solution
Scarpini E, Galimberti D, Ghezzi L. Drug Design, Development and Therapy. 2013:1471. 
. Kishi T, Matsunaga S, Oya K, Nomura I, et al. Journal of Alzheimers Disease. 2017;60(2):401-425. 
Memantine  [prescribing information]. Apotex. 2017. 
Current Therapeutic Management 
Memantine (Namenda®)
 Adverse Reactions: 
 ≥ 1% to 10%: Dizziness, headache, depression, 
hallucination, fatigue,  confusion, diarrhea, constipation, 
weight gain, 
 Monitoring parameters: cognitive function, functional such 
as activities of daily living (ADLs), periodic ophthalmic exam 
(Canadian labeling) 
Scarpini E, Galimberti D, Ghezzi L. Drug Design, Development and Therapy. 2013:1471. 
. Kishi T, Matsunaga S, Oya K, Nomura I, et al. Journal of Alzheimers Disease. 2017;60(2):401-425. 
Memantine  [prescribing information]. Apotex. 2017. 
Current Therapeutic Management 
 Combination Product: Donepezil & Memantine (Namzaric®)
 Indicated for treatment of moderate to severe dementia of  
Alzheimer’s Disease 
 For patient stabilized on donepezil 10 mg once daily 
 Available as extended release capsule
 See individual agents for adverse reactions and monitoring 
Scarpini E, Galimberti D, Ghezzi L. Drug Design, Development and Therapy. 2013:1471. 
. 
Namzaric [prescribing information]. Allergan. 2016. 
New Drug Targets 
Glutaminergic
Gamma-secretase 
inhibitors
BACE inhibitors 
Aβ Clearance
Tau stabilization 
Tau aggregation 
inhibition 
P-Tau 
clearance
Microglial activation 
inhibitors
Graham WV, Bonito-Oliva A, Sakmar TP et al. Annual Review of Medicine. 2017;68(1):413-430. 
New Drug Targets: Glutaminergic
 Probable 
pathophysiological 
mechanism of Alzheimer’s 
disease:
 Excess glutamate at 
excitatory synapses with 
associated cytotoxicity, 
possibly due to 
decreased glutamate 
reuptake from microglia   
Graham WV, Bonito-Oliva A, Sakmar TP et al. Annual Review of Medicine. 2017;68(1):413-430. 
New Drug Targets: Glutaminergic
 Riluzole
 Inhibitor of glutamate 
release
 Inhibitor of postsynaptic 
glutamate receptor 
signaling
 In Phase II trials for mild 
AD patients 
Graham WV, Bonito-Oliva A, Sakmar TP et al. Annual Review of Medicine. 2017;68(1):413-430. 
New Drug Targets: Gamma Secretase 
Inhibitors 
 Gamma secretase is responsible for cleaving up to 50 
different type I transmembrane protein substrates 
including APP and Notch Receptors
 Inhibition of proteolysis of Notch receptors can lead to 
toxic effects such as gastrointestinal bleeds and 
immunosuppression
Graham WV, Bonito-Oliva A, Sakmar TP et al. Annual Review of Medicine. 2017;68(1):413-430. 
New Drug Targets: Gamma Secretase 
Inhibitors 
 Semagacestat: discontinued 
 Failed to slow disease progression and worsen 
patient symptoms 
 Avagacestat: discontinued 
 Adverse effects: cerebral microbleeds, dose-
dependent glycosuria, and nonmelanoma skin 
cancer 
 EVP-0962: phase II 
 Does not affect the Notch receptor
Graham WV, Bonito-Oliva A, Sakmar TP et al. Annual Review of Medicine. 2017;68(1):413-430. 
New Drug Targets: BACE Inhibitors 
 β-site APP cleaving enzyme 1 (BACE1) is the first 
enzyme to cleave the APP protein 
 First generation BACE inhibitors failed 
 Low bioavailability and blood-brain barrier 
penetration 
 BI 1181181: discontinued 
Graham WV, Bonito-Oliva A, Sakmar TP et al. Annual Review of Medicine. 2017;68(1):413-430. 
New Drug Targets: BACE Inhibitors 
 Second generation BACE Inhibitors failed 
 More lipophilic
 Able to cross the blood brain barrier and endosomal 
membranes 
 Liver toxicity 
 RG7129: discontinued 
 LY2811376: discontinued 
 LY2886721: discontinued 
Graham WV, Bonito-Oliva A, Sakmar TP et al. Annual Review of Medicine. 2017;68(1):413-430. 
 Third generation BACE 
inhibitors 
 E2609: phase II
 AZD3293: phase III
 CNP520: phase II/III
 JNJ-54861911: phase II/III
 Verubecestat: phase III
 Anti-BACE antibodies 
(Abs) 
 High target specificity and 
in animal models reduced 
Aβ concentrations in 
periphery and brain
 Site directed Abs for 
BACE-APP complex 
 Targets the β-secretase 
cleavage site of APP
New Drug Targets: BACE Inhibitors 
Graham WV, Bonito-Oliva A, Sakmar TP et al. Annual Review of Medicine. 2017;68(1):413-430. 
New Drug Targets: Aβ Clearance
 Defective-Clearance 
Hypothesis: 
 Net Aβ content in the 
brain is determined by 
the equilibrium between 
the rate of production 
and clearance
 Deficient cerebrospinal 
fluid clearance of Aβ
has been found in 
cases of AD 
Graham WV, Bonito-Oliva A, Sakmar TP et al. Annual Review of Medicine. 2017;68(1):413-430. 
New Drug Targets: Aβ Clearance
 Defective-Clearance 
Hypothesis: 
 Aβ-degrading 
proteases (AβDPs)-
collective group of 
peptidases and 
proteinases that clear 
the Aβ
 Pharmacologic 
treatment to stimulate 
expression of AβDPs 
or inhibit endogenous 
inhibitors of AβDPs
Graham WV, Bonito-Oliva A, Sakmar TP et al. Annual Review of Medicine. 2017;68(1):413-430. 
New Drug Targets: Aβ Clearance
 Immunotherapy to increase Aβ clearance 
 AN-1792: discontinued 
 Full length synthetic human Aβ42 reduced Aβ formation 
 Active immunization 
 6% of patients developed severe meningoencephalitis 
Active 
Immunization 
Passive 
immunization 
Graham WV, Bonito-Oliva A, Sakmar TP et al. Annual Review of Medicine. 2017;68(1):413-430. 
New Drug Targets: Aβ Clearance
 Immunotherapy to increase Aβ clearance 
 Passive Immunization 
 Systemic infusion of monoclonal Abs (mAbs)
 Prevents oligomerization and fibril formation and 
dissolves aggregates
 Low blood brain barrier penetration, high specificity, 
affinity toward their antigen, low toxicity, and good 
plasma pharmacokinetics 
Graham WV, Bonito-Oliva A, Sakmar TP et al. Annual Review of Medicine. 2017;68(1):413-430. 
New Drug Targets: Aβ Clearance
 How does it 
work? 
 Microglia 
activation 
through Fc 
receptors
 Peripheral 
sink effect
Graham WV, Bonito-Oliva A, Sakmar TP et al. Annual Review of Medicine. 2017;68(1):413-430. 
New Drug Targets: Aβ Clearance
N-terminal Epitope 
 AAB-003: phase I 
 Bapineuzumab: 
discontinued
 Dependent on ApoE4 
genotype 
 Risk of vasogenic 
cerebral edema 
 GSK933776: discontinued
Central Epitope
 Aducanumab: phase III
 Ban2401: phase II
 Crenezumab: phase III
 No vasogenic cerebral 
edema
 Gantenerumab: phase III
 Recognizes N-terminal tail 
and central region
 Solanezumab: discontinued
Graham WV, Bonito-Oliva A, Sakmar TP et al. Annual Review of Medicine. 2017;68(1):413-430. 
New Drug Targets: Tau Stabilization
 Hyperphosphorylated tau leads to cytoskeleton disruptions 
along axons
 Therapeutic approach to re-stabilize microtubules 
 Epothilone D: discontinued
 Paclitaxel-derived product 
 Reduced transport deficits and cognitive impairment in 
tau transgenic mice 
 Good penetration into brain 
 Evaluated in phase I, but not being pursued
Graham WV, Bonito-Oliva A, Sakmar TP et al. Annual Review of Medicine. 2017;68(1):413-430. 
New Drug Targets: Tau Aggregation 
Inhibitor 
 Derivatives of methylene blue have been shown to 
disrupt the aggregation of tau
 Reduces oxidative stress
 Prevents mitochondrial damage 
 Preserves cognitive function in mice
Graham WV, Bonito-Oliva A, Sakmar TP et al. Annual Review of Medicine. 2017;68(1):413-430. 
New Drug Targets: Tau Aggregation 
Inhibitor 
 Rember TM: discontinued
 First generation 
 TRx0237: phase III
 Second generation 
Graham WV, Bonito-Oliva A, Sakmar TP et al. Annual Review of Medicine. 2017;68(1):413-430. 
New Drug Targets: P-Tau Clearance
Active Immunization 
Vaccines
 AADvac-1: phase II
 ACI-35: phase I 
Passive Immunization 
 Generalized into four 
categories
 Hyperphosphorylated
tau
 Conformation of tau
 Fragments of tau
 Total tau
Graham WV, Bonito-Oliva A, Sakmar TP et al. Annual Review of Medicine. 2017;68(1):413-430. 
New Drug Targets: Microglia Inhibitors
 Neuroinflammation in response to Aβ induces the 
activation of microglia and the recruitment of astrocytes to 
the sites where Aβ deposits occur
 Microglia enters a hyper-reactive state in 
neurodegenerative conditions and aging
 Sustained over-production of microglial pro-inflammatory 
mediators is neurotoxic
Graham WV, Bonito-Oliva A, Sakmar TP et al. Annual Review of Medicine. 2017;68(1):413-430. 
New Drug Targets: Microglia Inhibitors
 Alzhemed: discontinued
 Phase III trial showed tolerability & safety study 
inactive 
 Azeliragon: phase III
 Inhibitor of receptor for advanced glycation end 
products (RAGE) preventing inflammation and oxidative 
damage 
Graham WV, Bonito-Oliva A, Sakmar TP et al. Annual Review of Medicine. 2017;68(1):413-430. 
New Drug Targets: Microglia Inhibitors
 No evidence supports the use of NSAIDs in reducing  
neuroinflammation 
 Ibuprofen: discontinued
 Flurizan: discontinued
Graham WV, Bonito-Oliva A, Sakmar TP et al. Annual Review of Medicine. 2017;68(1):413-430. 
New Drug Targets: Glycogen Synthase 
Kinase Inhibitor 
 Glycogen Synthase Kinase 3 (GSK-3) leads to the 
hyperphosphorylation of tau
 Lithium is a GSK-3 inhibitor
 Lithium is a narrow therapeutic drug and not well tolerated 
 Studies of micro-doses of lithium have demonstrated 
improvement in cognitive studies 
 Studies limited by sample sizes and not FDA approved for 
treatment in AD
Allgaier M. Frontiers in Bioscience. 2014;19(8):1345. 
New Drug Targets: Phase II/III or III
Allgaier M. Frontiers in Bioscience. 2014;19(8):1345. 
BACE Inhibitors 
• AZD 3293
• CNP520
• JNJ-54861911
• Verubecestat
Immunotherapy Aβ Clearance 
• Crenezumanb
• Gantenerumab
• Aducanumab
Tau Aggregation Inhibitors 
• TRx0237
Microglial Inhibitors
• Azeliragon
New Drug Targets: Phase II
Allgaier M. Frontiers in Bioscience. 2014;19(8):1345. 
Glutaminergic 
• Riluzole 
Gamma Secretase Inhibitor 
• EVP-0962 
BACE Inhibitor 
• E2609
Immunotherapy Aβ Clearance 
• Ban2401
Active Immunization Vaccines: P-Tau Clearance 
• AADvac-1
Clinical Impact of Current Medications
 Current FDA approved medications for Alzheimer’s disease 
only manages symptoms and does not slow or prevent the 
progression of neurodegeneration
 Cognitive decline of Alzheimer’s disease commonly appear 
years after the pathophysiological progression 
 Once Alzheimer’s disease has severely progressed the use 
of FDA approved medications, such as the ACEI and NMDA 
antagonists, may not benefit the patient 
Birks J, Harvey R. Cochrane Database of Systematic Reviews. 2018;(6). 
Clinical Impact of Current Medications
 Dependent on the clinical manifestation of cognitive 
impairment
 Used during the late stages of Alzheimer’s disease 
 Limited evidence on the specific time frame to discontinue 
treatment 
 Reasonable to stop a medication when….
 No noticeable benefit after the first three months of 
treatment
 Dementia progresses to a point where there would be no 
meaningful benefit from continued therapy
Birks J, Harvey R. Cochrane Database of Systematic Reviews. 2018;(6). 
Kishi T, Matsunaga S, Oya K, Nomura I, et al. Journal of Alzheimers Disease. 2017;60(2):401-425. 
Clinical Impact of New Drug Targets 
 New Drug targets intended to use as disease-modifying 
treatment 
 Limitation
 Benefit expected to be seen if used during early stages 
of Alzheimer’s disease prior to development of cognitive 
impairment
 Requires ability to find biomarkers to detect 
development  of Alzheimer’s disease 
• PET Scanning 
• CSF 
Khoury R, Patel K, Gold J, et al. Drugs & Aging. 2017;34(11):811-820. 
Clinical Impact: Brigham & Women’s Trial 
 A4 Trial 
 Anti-Amyloid treatment in Asymptomatic Alzheimer’s 
disease
 Targeting early detection of amyloid plaques for 
prevention of cognitive impairment associated with 
Alzheimer’s disease 
 Positron emission tomography (PET) scans that can 
identify plaque buildup
 Multi-site, randomized double-blind study, enrolling 
1000 patients ages 65-85
 Half randomized to solanezumab vs. placebo 
Brigham and Women’s Hospital. A4 study. 2017. 
Clinical Impact- PET SCANNING  
Khoury R, Patel K, Gold J, et al. Drugs & Aging. 2017;34(11):811-820. 
Brigham and Women’s Hospital. A4 study. 2017. 
Clinical Impact 
Use multiple medications with 
varying targets to prevent 
progression of Alzheimer’s 
disease 
Will changes in concentration 
of amyloid plaques or use of 
biomarkers be indicative of 
clinical outcomes? 
Aβ
Tau
NeuroInflammation
Khoury R, Patel K, Gold J, et al. Drugs & Aging. 2017;34(11):811-820. 
Conclusion  
 As life expectancy increases, Alzheimer’s disease will 
become more of an epidemic 
 All causes of Alzheimer’s disease are still not known, but 
associated with amyloid plaques and neurofibrillary tangles 
 Current treatment for Alzheimer’s disease are only 
symptomatic and often used in response to cognitive 
impairment 
Conclusion  
 Development of multiple new drug targets for Alzheimer's 
disease are entering phase II/III clinical trials
 New drug targets intended for use as disease modifying 
treatments and will require early detection of Alzheimer’s 
disease 
True or False Questions   
 Once initiated, donepezil and memantine should be 
given indefinitely for the treatment of Alzheimer’s 
disease regardless of cognitive function. 
 Lithium in microdoses is FDA approved for 
prevention of Alzheimer’s disease, it works by 
reducing hyperphosphorylation of tau through 
glycogen synthase inhibition
 Amyloid directed active immunotherapy treatment 
reduces β-amyloid plaque formation but can lead to 
the development of meningoencephalitis
True or False Questions   
 FALSE: Once initiated, donepezil and memantine
should be given indefinitely for the treatment of 
Alzheimer’s disease regardless of cognitive function. 
 FALSE: Lithium in microdoses is FDA approved for 
prevention of Alzheimer’s disease, it works by 
reducing hyperphosphorylation of tau through 
glycogen synthase inhibition
 TRUE: Amyloid directed active immunotherapy 
treatment reduces β-amyloid plaque formation but 
can lead to the development of 
meningoencephalitis
THANK YOU
Questions? 
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